Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Diagnosis: LymphomaNCT ID: NCT01953692
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-432
The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDA®) in hematologic malignancies. The primary study hypotheses are that treatment with pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate (ORR) or Complete Remission Rate (CRR).
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center
Overall PI: Philippe Armand, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: David Avigan, MD,
Beth Israel Deaconess Medical Center
Contacts: Dana-Farber Cancer Institute:
firstname.lastname@example.orgBeth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060